Compare PDC & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDC | CLRB |
|---|---|---|
| Founded | 2018 | 2002 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2M | 24.5M |
| IPO Year | 2022 | 2008 |
| Metric | PDC | CLRB |
|---|---|---|
| Price | $3.30 | $1.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 33.3K | ★ 45.2K |
| Earning Date | 07-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.42 | $1.96 |
| 52 Week High | $8.40 | $6.52 |
| Indicator | PDC | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 48.25 | 16.65 |
| Support Level | $2.64 | N/A |
| Resistance Level | $3.64 | $2.70 |
| Average True Range (ATR) | 0.44 | 0.13 |
| MACD | 0.08 | -0.05 |
| Stochastic Oscillator | 34.74 | 1.49 |
Perpetuals.com Ltd is a financial technology company bridging traditional financial markets with blockchain-based infrastructure. The group operates regulated financial market infrastructure at the intersection of traditional finance and digital assets. Its B2B offerings include capital markets technology delivered as SaaS and institutional-grade custody through Crypto Vault. For consumers, it provides compliant retail trading and prediction market platforms. The group's operations across the USA, Europe, and Asia develop software solutions that enable regulated trading venues to operate with 24/7 self-clearing and blockchain-based settlement technology, empowering institutions to compete in the evolving landscape of digital finance.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.